今天，医疗技术初创企业 AWAK Technologies 宣布获得 1120
万美元融资(博主註: 5 個月後即增加至112億美元, 見下文)，由淡马锡控股全资子公司 Accuron Technologies Limited 旗下的 Accuron MedTech
领投，另有其它投资人参投。
AWAK 创立于 2007
年，总部位于加利福尼亚州，同时在新加坡设有办事处，
这一技术具有颠覆性意义，
AWAK 总裁 Gordon Ku 博士表示：“公司技术平台面向的是价值约 850
亿美元的末期肾病患者市场，本轮融资有助于我们在 2018 年之前完成产品研发和开发计划，并与 Accuron MedTech
共同将这些产品推向市场。”
Accuron MedTech 的集团 CEO Abel Ang 表示：“Accuron MedTech
是全球肾结石疾病解决方案的领先企业，AWAK 技术有助于我们迈向更广阔的肾病市场。本次领投 AWAK
的融资，是因为我们两个企业之间存在很多协同效应，
2011 年 1 月份，AWAK 曾获得 600
万美元种子轮融资。未来，公司还将构建电池驱动的透析机设备，
----------------------------------------------------------------------------------------------------------
AWAK Technology receives a mammoth funding of $11.2 Bn from Accuron Technologies
18 May 2017
轉載自: https://www.biospectrumasia.com/news/27/8932/awak-technology-receives-a-mammoth-funding-of-11-2-bn-from-accuron-technologies-.html
AWAK Technology receives a mammoth funding of $11.2 Bn from Accuron
Technologies The investment was made through the MedTech Alliance,
an accelerator appointed by SPRING SEEDS Capital, to facilitate the
growth of start-ups in the local medtech industry.
Accuron MedTech, a division of Accuron Technologies Limited, has
invested a massive amount of US $11.2 billion in a Singapore based
medtech startup AWAK Technologies. This funding will support the
commercialization of AWAK Technologies’ disruptive sorbent
regenerative technology that aims to improve dialysis treatment
options for patients suffering from kidney failure.
Accuron MedTech joins existing shareholders of AWAK Technologies,
which include Baxter Healthcare SA and TP Innovation Holdings Pte
Ltd. This is the seventh medtech investment/ divestment transaction
that Accuron MedTech has made in the last three years.
The investment was made through the MedTech Alliance, an
accelerator appointed by SPRING SEEDS Capital, to facilitate the
growth of start-ups in the local medtech industry.
AWAK Technologies has developed a sorbent technology platform that
has applications in both hemodialysis and peritoneal dialysis for
the removal of toxins from patients suffering from kidney failure.
The sorbent technology regenerates and reconstitutes used dialysis
fluid into fresh fluid, which means more efficient dialysis with up
to 90 per cent less dialysis fluid compared to conventional
dialysis machines. This has the potential to make a significant
impact by reducing the cost and complexity of dialysis, while at
the same time increasing miniaturization and portability of
dialysis machines.
“Accuron MedTech, through Dornier MedTech, is a global leader in
providing treatment solutions in the US$400 million kidney stone
market. AWAK Technologies is our first step in diversifying into
the wider kidney disease market,” said Abel Ang, Group Chief
Executive Officer, Accuron MedTech, a division of Accuron
Technologies.
He further added that the company sees great synergies amongst its
portfolio companies, which can leverage upon each other for
development capabilities, networks and manufacturing. Accuron looks
forward to partnering with AWAK Technologies’ Board and management
in bringing its products to market.
-----------------------------------------------------------------------------------------------------
延伸閱讀: http://awak.com/product
博主觀察:
-----------------------------------------------------------------------------------------------------
延伸閱讀: http://awak.com/product
博主觀察:
